Search

Herbert K Struemper

from Chapel Hill, NC
Age ~60
Get Report
Also known as:
Halbert K Struemper, Hubbard K Struemper, Herbert K Herbert, Herbert Strumper, Herbert R, Halbert R
Phone and address:
109 Forest Ridge Dr, Chapel Hill, NC 27514
(610) 246-6828
Related to:
Andrew S KovatchHeidi Mitchell, 58Andrea C Wuerth, 60Julian M Wuerth, 55Hans M Wuerth, 87Ursula E Wuerth, 86Andrea C Wuerth, 60Milena Wuerth
Connected to:
Angela Struemph, 53David Struempf, 61Jake J Struempler, 50Maynard D Struempler, 76Michael D Struempler, 73Scott G Struemph, 55Shirley D Struemph, 68Steve P Struempler, 68Scott M Struessel, 47William F Struett, 62

Herbert Struemper Phones & Addresses

  • 109 Forest Ridge Dr, Chapel Hill, NC 27514 (610) 246-6828
  • 40 E North St, Bethlehem, PA 18018 (610) 868-0955
  • 1245 Hoover St, Menlo Park, CA 94025
  • 23 Duane St, Redwood City, CA 94062
  • 4320 Rowalt Dr, College Park, MD 20740
  • Northampton, PA
  • Pasadena, CA
  • Walla Walla, WA
  • 109 Forest Ridge Dr, Chapel Hill, NC 27514 (610) 868-0955

Work

Company: Glaxosmithkline Jan 2009 Position: Principal clinical pharmacokineticist

Education

Degree: Postdoc School / High School: California Institute of Technology 1997 to 1999 Specialities: Systems & Control Theory

Skills

Pk/Pd • Clinical Trials • Pharmacometrics • Systems Biology • Clinical Pharmacology • Drug Metabolism • Nonmem • Modeling • Biostatistics • Winnonlin • Drug Discovery • Oncology • Drug Development • Clinical Development • Simulation • Pharmacodynamics • Pharmacology • Simulations • Pharmaceutical Industry • Control Engineering • Biomarkers • Pharmacokinetics

Languages

German

Industries

Pharmaceuticals

Resumes

Resumes

Herbert Struemper Photo 1

Director, Clinical Pharmacology Modeling And Simulation

View page
Location:
14800 Charlson Rd, Eden Prairie, MN 55347
Industry:
Pharmaceuticals
Work:
GlaxoSmithKline since Jan 2009
Principal Clinical Pharmacokineticist
Pharsight Corp. Sep 2007 - Dec 2008
Senior Associate Scientist
Entelos Inc. 1999 - 2007
Senior Biosystems Engineer
Education:
California Institute of Technology 1997 - 1999
Postdoc, Systems & Control Theory University of Maryland College Park 1994 - 1997
Phd., Electrical Engineering (Systems & Control Theory) Technische Universität Berlin
Diplom Ingenieur, Electrical Engineering (Systems & Control Theory)
Skills:
Pk/Pd
Clinical Trials
Pharmacometrics
Systems Biology
Clinical Pharmacology
Drug Metabolism
Nonmem
Modeling
Biostatistics
Winnonlin
Drug Discovery
Oncology
Drug Development
Clinical Development
Simulation
Pharmacodynamics
Pharmacology
Simulations
Pharmaceutical Industry
Control Engineering
Biomarkers
Pharmacokinetics
Languages:
German

Publications

Us Patents

Method And Apparatus For Computer Modeling A Joint

View page
US Patent:
7472050, Dec 30, 2008
Filed:
Feb 11, 2005
Appl. No.:
11/056952
Inventors:
Nadine A. Defranoux - San Francisco CA, US
Todd B. Dubnicoff - Burlingame CA, US
Annette K. Lewis - Menlo Park CA, US
Thomas S. Paterson - West Hollywood CA, US
Saroja Ramanujan - San Mateo CA, US
Lisl K. M. Shoda - Redwood City CA, US
Karl Petter Soderstrom - San Francisco CA, US
Herbert K. Struemper - Menlo Park CA, US
Assignee:
Entelos, Inc. - Foster City CA
International Classification:
G06G 7/48
US Classification:
703 11, 703 2
Abstract:
The present invention relates to a mathematical and computer model of a joint. The model includes representation of the biological processes related to the synovial tissue and cartilage. In one embodiment, the model represents a human joint afflicted with rheumatoid arthritis.

Method And Apparatus For Computer Modeling A Joint

View page
US Patent:
20030078759, Apr 24, 2003
Filed:
May 22, 2002
Appl. No.:
10/154123
Inventors:
Nadine Defranoux - San Francisco CA, US
Todd Dubnicoff - Burlingame CA, US
David Klinke - San Bruno CA, US
Annette Lewis - Menlo Park CA, US
Thomas Paterson - West Hollywood CA, US
Saroja Ramanujan - San Mateo CA, US
Lisl Shoda - Redwood City CA, US
Karl Soderstrom - San Francisco CA, US
Herbert Struemper - Menlo Park CA, US
International Classification:
G06G007/48
US Classification:
703/011000
Abstract:
The present invention relates to a mathematical and computer model of a joint. The model includes representation of the biological processes related to the synovial tissue and cartilage. In one embodiment, the model represents a human joint afflicted with rheumatoid arthritis.

Method And Apparatus For Computer Modeling Of An Adaptive Immune Response

View page
US Patent:
20030104475, Jun 5, 2003
Filed:
Jun 28, 2002
Appl. No.:
10/186938
Inventors:
Scott Kelly - Champaign IL, US
David Klinke - San Bruno CA, US
Clement Leong - Erskineville, AU
Annette Lewis - Menlo Park CA, US
Miles Okino - Belmont CA, US
Thomas Paterson - West Hollywood CA, US
Lisl Shoda - Redwood City CA, US
Cynthia Stokes - Menlo Park CA, US
Herbert Struemper - Menlo Park CA, US
International Classification:
G01N033/53
G01N033/50
US Classification:
435/007100, 435/004000, 702/019000
Abstract:
The present invention relates generally to a computer model of an adaptive immune response. One embodiment of the invention relates to a computer model of an adaptive immune response within the framework of signals conveyed at the site of antigen exposure. Another embodiment of the model includes a representation of complex physiological regulatory mechanisms related to, for example, cellular dynamics, mediator production, antigen-presenting cell (APC) recruitment, APC maturation, lymphocyte activation, lymphocyte trafficking, and/or lymphocyte effector function. In another embodiment, the model can account for mediator production in response to antigen within a chronically inflamed peripheral tissue, as well as the regulatory effects of mediators on APC and lymphocyte population dynamics, including maturation, activation, and apoptosis, and the regulatory effects of mediators produced by APCs and lymphocytes on a chronically inflamed peripheral tissue. Another embodiment of the invention relates to an analytical model of an adaptive immune response.

Treatment Of Rheumatoid Arthritis With Galectin-3 Antagonists

View page
US Patent:
20050158321, Jul 21, 2005
Filed:
Dec 17, 2004
Appl. No.:
11/017213
Inventors:
Vincent Hurez - Albany CA, US
Seth Michelson - San Jose CA, US
Herbert Struemper - Bethlehem PA, US
Leif Wennerberg - Mountain View CA, US
Assignee:
Entelos, Inc. - Foster City CA
International Classification:
A61K048/00
A61K031/70
A61K039/395
US Classification:
424146100, 514044000, 514023000
Abstract:
The invention encompasses a novel method of treating an inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases, such as rheumatoid arthritis, and their clinical symptoms. The inventors have made the discovery that the activity of galectin-3, a β-galactoside-binding lectin known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of galectin-3.

Treatment Of Rheumatoid Arthritis With Soluble Fas-Ligand Cross-Linkers

View page
US Patent:
20050159357, Jul 21, 2005
Filed:
Dec 17, 2004
Appl. No.:
11/017211
Inventors:
Vincent Hurez - Albany CA, US
Seth Michelson - San Jose CA, US
Lisl Shoda - Menlo Park CA, US
Herbert Struemper - Bethlehem PA, US
Leif Wennerberg - Mountain View CA, US
Assignee:
Entelos, Inc. - Foster City CA
International Classification:
A61K048/00
A61K038/19
A61K038/17
US Classification:
514012000, 514044000
Abstract:
The invention encompasses novel methods of treating rheumatoid arthritis and its symptoms and novel methods of identifying and screening for drugs useful in the treatment of rheumatoid arthritis and its clinical symptoms. Targeted manipulation of a computer model of a human rheumatic joint provided the surprising result that cross-linking soluble Fas-ligand (sFasL) has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of rheumatoid arthritis may be alleviated by administering a sFasL-specific cross-linker.

Treatment Of Rheumatoid Arthritis With Soluble Fas-Ligand Cross-Linkers

View page
US Patent:
20080118466, May 22, 2008
Filed:
Jun 8, 2007
Appl. No.:
11/760599
Inventors:
Vincent Jacques Hurez - Albany CA, US
Seth G. Michelson - San Jose CA, US
Lisl Katharine Shoda - Menlo Park CA, US
Herbert Struemper - Bethlehem PA, US
Leif Gustaf Wennerberg - Mountain View CA, US
International Classification:
A61K 38/16
A61K 38/21
A61K 31/7088
A61K 31/445
A61K 31/513
A61K 31/704
A61K 33/24
A61K 31/4985
G01N 33/53
A61P 19/02
US Classification:
424 856, 514 12, 514 44, 514348, 514274, 514 34, 424649, 514249, 435 71
Abstract:
The invention encompasses novel methods of treating rheumatoid arthritis and its symptoms and novel methods of identifying and screening for drugs useful in the treatment of rheumatoid arthritis and its clinical symptoms. Targeted manipulation of a computer model of a human rheumatic joint provided the surprising result that cross-linking soluble Fas-ligand (sFasL) has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of rheumatoid arthritis may be alleviated by administering a sFasL-specific cross-linker.

Method And Apparatus For Computer Modeling Of An Adaptive Immune Response

View page
US Patent:
20080201122, Aug 21, 2008
Filed:
Oct 4, 2007
Appl. No.:
11/867658
Inventors:
Scott D. Kelly - Champaign IL, US
David J. Klinke - San Bruno CA, US
Clement Leong - Erskineville, AU
Annette K. Lewis - Menlo Park CA, US
Miles S. Okino - Belmont CA, US
Thomas S. Paterson - Redondo Beach CA, US
Lisl K.M. Shoda - Redwood City CA, US
Cynthia Stokes - Menlo Park CA, US
Herbert K. Struemper - Menlo Park CA, US
International Classification:
G06G 7/60
US Classification:
703 11
Abstract:
The present invention relates generally to a computer model of an adaptive immune response. One embodiment of the invention relates to a computer model of an adaptive immune response within the framework of signals conveyed at the site of antigen exposure. Another embodiment of the model includes a representation of complex physiological regulatory mechanisms related to, for example, cellular dynamics, mediator production, antigen-presenting cell (APC) recruitment, APC maturation, lymphocyte activation, lymphocyte trafficking, and/or lymphocyte effector function. In another embodiment, the model can account for mediator production in response to antigen within a chronically inflamed peripheral tissue, as well as the regulatory effects of mediators on APC and lymphocyte population dynamics, including maturation, activation, and apoptosis, and the regulatory effects of mediators produced by APCs and lymphocytes on a chronically inflamed peripheral tissue. Another embodiment of the invention relates to an analytical model of an adaptive immune response.

Treatment Of Rheumatoid Arthritis With Galectin-3 Antagonists

View page
US Patent:
20080213786, Sep 4, 2008
Filed:
Apr 11, 2008
Appl. No.:
12/082508
Inventors:
Vincent Jacques Hurez - Albany CA, US
Seth G. Michelson - San Jose CA, US
Herbert Struemper - Bethlehem PA, US
Leif Gustaf Wennerberg - Mountain View CA, US
Assignee:
Entelos, Inc. - Foster City CA
International Classification:
C12Q 1/68
C12Q 1/02
G01N 33/53
G01N 33/00
US Classification:
435 6, 435 29, 435 724, 436 86
Abstract:
The invention encompasses a novel method of treating an inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases, such as rheumatoid arthritis, and their clinical symptoms. The inventors have made the discovery that the activity of galectin-3, a β-galactoside-binding lectin known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of galectin-3.
Control profile
Herbert K Struemper from Chapel Hill, NC, age ~60 Get Report